CMS approves coverage for Recor Medical renal denervation study
November 21, 2025
Recor Medical said today that it secured Medicare approval, granting coverage for the company’s RADIANCE CED study.
Recor Medical said today that it secured Medicare approval, granting coverage for the company’s RADIANCE CED study.
Overture’s DaVitri system aims to make egg thawing and freezing processes during IVF more consistent to improve successful embryo formation outcomes.
QuantalX’s Delphi-MD is applicable for the diagnosis, monitoring, and treatment evaluation of a range of neurological conditions.
Scientists have been able to measure the electrical signals in the “second brain in our guts” for the first-ever time, giving renewed understanding to its interconnection with the brain.
Paradromics announced today that it received FDA investigational device exemption (IDE) to begin a study of its brain-computer interface (BCI).
EDAP TMS SA (Nasdaq:EDAP) announced today that the FDA granted 510(k) clearance for new workflows for its ultrasound technology.
Significant milestone reached in advancing a driverless total artificial heart, strengthening Picard Medicals leadership in total artificial heart technology
A new study has shown that a clinical tool developed by the University of Liverpool and The Walton Center can accurately predict whether the most common type of brain tumor will grow or cause symptoms, helping doctors and patients make better-informed decisions about care.
A patented RNA-based cocktail developed at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has emerged as a promising active agent against tumors of the central nervous system, such as glioblastoma.
Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger RNA—best known for being used in COVID-19 vaccines—in the hopes of finding a breakthrough treatment for a particularly deadly cancer.